Michael Capuzzo, a New York Times best-selling author, has just published an article titled “The Drug That Cracked Covid”. The 15-page article chronicles the gargantuan struggle being waged by frontline doctors on all continents to get ivermectin approved as a Covid-19 treatment, as well as the tireless efforts by reporters, media outlets and social media companies to thwart them.
Because of ivermectin, Capuzzo says, there are “hundreds of thousands, actually millions, of people around the world, from Uttar Pradesh in India to Peru to Brazil, who are living and not dying.” Yet media outlets have done all they can to “debunk” the notion that ivermectin may serve as an effective, easily accessible and affordable treatment for Covid-19. They have parroted the arguments laid out by health regulators around the world that there just isn’t enough evidence to justify its use.
For his part, Capuzzo, as a reporter, “saw with [his] own eyes the other side [of the story]” that has gone unreported, of the many patients in the US whose lives have been saved by ivermectin and of five of the doctors that have led the battle to save lives around the world, Paul Marik, Umberto Meduri, José Iglesias, Pierre Kory and Joe Varon. These are all highly decorated doctors. Through their leadership of the Front Line COVID-19 Critical Care (FLCCC) Alliance, they have already enhanced our treatment of Covid-19 by discovering and promoting the use of Corticoid steroids against the virus. But their calls for ivermectin to also be used have met with a wall of resistance from healthcare regulators and a wall of silence from media outlets.
“I really wish the world could see both sides,” Capuzzo laments. But unfortunately most reporters are not interested in telling the other side of the story. Even if they were, their publishers would probably refuse to publish it.
That may explain why Capuzzo, a six-time Pulitzer-nominated journalist best known for his New York Times-bestselling nonfiction books Close to Shore and Murder Room, ended up publishing his article on ivermectin in Mountain Home, a monthly local magazine for the of the Pennsylvania mountains and New York Finger Lakes region, of which Capuzzo’s wife is the editor. It’s also the reason why I decided to dedicate today’s post to Capuzzo’s article. Put simply, as many people as possible –particularly journalists — need to read his story.
As Capuzzo himself says, “I don’t know of a bigger story in the world.”
Total News Blackout
On December 8 2020, FLCCC member Dr Pierre Kory gave nine minutes of impassioned testimony to the US Homeland Security Committee Meeting on the potent anti-viral, anti-inflammatory benefits of ivermectin. A total of 9 million people (myself included) saw the video on YouTube before it was taken down by YouTube’s owner, Google. As Capuzzo exhaustively lays out, both traditional and social media have gone to extraordinary lengths to keep people in the dark about ivermectin. So effective has this been that even in some of the countries that have benefited most from its use (such as Mexico and Argentina) many people are completely unaware of its existence. And this is no surprise given how little information is actually seeping out into the public arena.
A news blackout by the world’s leading media came down on Ivermectin like an iron curtain. Reporters who trumpeted the COVID-19 terror in India and Brazil didn’t report that Ivermectin was crushing the P-1 variant in the Brazilian rain forest and killing COVID-19 and all variants in India. That Ivermectin was saving tens of thousands of lives in South America wasn’t news, but mocking the continent’s peasants for taking horse paste was. Journalists denied the world knowledge of the most effective life-saving therapies in the pandemic, Kory said, especially among the elderly, people of color, and the poor, while wringing their hands at the tragedy of their disparate rates of death.
Three days after Kory’s testimony, an Associated Press “fact-check reporter” interviewed Kory “for twenty minutes in which I recounted all of the existing trials evidence (over fifteen randomized and multiple observational trials) all showing dramatic benefits of Ivermectin,” he said. Then she wrote: “AP’S ASSESSMENT: False. There’s no evidence Ivermectin has been proven a safe or effective treatment against COVID-19.” Like many critics, she didn’t explore the Ivermectin data or evidence in any detail, but merely dismissed its “insufficient evidence,” quoting instead the lack of a recommendation by the NIH or WHO. To describe the real evidence in any detail would put the AP and public health agencies in the difficult position of explaining how the lives of thousands of poor people in developing countries don’t count in these matters.
Not just in media but in social media, Ivermectin has inspired a strange new form of Western and pharmaceutical imperialism. On January 12, 2021, the Brazilian Ministry of Health tweeted to its 1.2 million followers not to wait with COVID-19 until it’s too late but “go to a Health Unit and request early treatment,” only to have Twitter take down the official public health pronouncement of the sovereign fifth largest nation in the world for “spreading misleading and potentially harmful information.” (Early treatment is code for Ivermectin.) On January 31, the Slovak Ministry of Health announced its decision on Facebook to allow use of Ivermectin, causing Facebook to take down that post and removed the entire page it was on, the Ivermectin for MDs Team, with 10,200 members from more than 100 countries.
In Argentina, Professor and doctor Hector Carvallo, whose prophylactic studies are renowned by other researchers, says all his scientific documentation for Ivermectin is quickly scrubbed from the Internet. “I am afraid,” he wrote to Marik and his colleagues, “we have affected the most sensitive organ on humans: the wallet…” As Kory’s testimony was climbing toward nine million views, YouTube, owned by Google, erased his official Senate testimony, saying it endangered the community. Kory’s biggest voice was silenced.
“The Most Powerful Entity on Earth”
Malcom X once called the media “the most powerful entity on the earth.” They have, he said, “the power to make the innocent guilty and to make the guilty innocent, and that’s power. Because they control the minds of masses”. Today, that power is now infused with the power of the world’s biggest tech and social media companies. Together social and traditional media have the power to make a medicine that has saved possibly millions of lives during the current pandemic disappear from the conversation. When it is covered, it’s almost always in a negative light. Some media organizations, including the NY Times, have even prefaced mention of the word “ivermectin” — a medicine that has done so much good over its 40-year lifespan that its creators were awarded the Nobel Prize for Medicine in 2015 — with the word “controversial.”
Undeterred, many front-line doctors have tried to persuade their respective health regulators of the unparalleled efficacy and safety of ivermectin as a covid treatment. They include Dr. Tess Lawrie, a prominent independent medical researcher who, as Capuzzo reports, evaluates the safety and efficacy of drugs for the WHO and the National Health Service to set international clinical practice guidelines:
“[She] read all twenty-seven of the Ivermectin studies Kory cited. The resulting evidence is consistent and unequivocal,” she announced, and sent a rapid meta-analysis, an epidemiolocal statistical multi-study review considered the highest form of medical evidence, to the director of the NHS, members of parliament, and a video to Prime Minister Boris Johnson with “the good news… that we now have solid evidence of an effective treatment for COVID-19…” and Ivermectin should immediately “be adopted globally and systematically for the prevention and treatment of COVID-19.”
Ignored by British leaders and media, Lawrie convened the day-long streaming BIRD conference—British Ivermectin Recommendation Development—with more than sixty researchers and doctors from the U.S., Canada, Mexico, England, Ireland, Belgium, Argentina, South Africa, Botswana, Nigeria, Australia, and Japan. They evaluated the drug using the full “evidence-to-decision framework” that is “the gold standard tool for developing clinical practice guidelines” used by the WHO, and reached the conclusion that Ivermectin should blanket the world.
“Most of all you can trust me because I am also a medical doctor, first and foremost,” Lawrie told the prime minster, “with a moral duty to help people, to do no harm, and to save lives. Please may we start saving lives now.” She heard nothing back.
Ivermectin’s benefits were also corroborated by Dr. Andrew Hill, a renowned University of Liverpool pharmacologist and independent medical researcher, and the senior World Health Organization/UNITAID investigator of potential treatments for COVID-19. Hill’s team of twenty-three researchers in twenty-three countries had reported that, after nine months of looking for a COVID-19 treatment and finding nothing but failures like Remdesivir— “we kissed a lot of frogs”— Ivermectin was the only thing that worked against COVID-19, and its safety and efficacy were astonishing—“blindingly positive,” Hill said, and “transformative.” Ivermectin, the WHO researcher concluded, reduced COVID-19 mortality by 81 percent.
Why All the Foot Dragging?
Yet most health regulators and governments continue to drag their feet. More evidence is needed, they say. All the while, doctors in most countries around the world have no early outpatient medicines to draw upon in their struggle against the worst pandemic in century. Drawing on his own experience, Capuzzo describes the absence of treatments for COVID-19 as a global crisis:
When my daughter Grace, a vice president at a New York advertising agency, came
down with COVID-19 recently, she was quarantined in a “COVID hotel” in Times Square with homeless people and quarantining travelers. The locks on her room door were removed. Nurses prowled the halls to keep her in her room and wake her up every night to check her
vitals—not to treat her, because there is no approved treatment for COVID-19; only, if her oxygen plummeted, to move her to the hospital, where there is only a single eective approved treatment for COVID-19, steroids that may keep the lungs from failing.
There are three possible explanations for health regulators’ refusal to allow the use of a highly promising, well-tolerated off-label medicine such as ivermectin:
As a generic, ivermectin is cheap and widely available, which means there would be a lot less money to be made by Big Pharma if it became the go-to early-stage treatment against covid.
Other pharmaceutical companies are developing their own novel treatments for Covid-19 which would have to compete directly with ivermectin. They include ivermectin’s original manufacturer, Merck, which has an antiviral compound, molnupiravir, in Phase 3 clinical trials for COVID-19. That might explain the company’s recent statement claiming that there is “no scientific basis whatsoever for a potential therapeutic effect of ivermectin against COVID-19.
If approved as a covid-19 treatment, ivermectin could even threaten the emergency use authorisation granted to covid-19 vaccines. One of the basic conditions for the emergency use authorisation granted to the vaccines currently being used against covid is that there are no alternative treatments available for the disease. As such, if ivermectin or some other promising medicine such as fluvoxamine were approved as an effective early treatment for Covid-19, the vaccines could be stripped of authorisation.
This may explain why affordable, readily available and minimally toxic drugs are not repurposed for use against Covid despite the growing mountains of evidence supporting their efficacy.
Ivermectin has already been approved as a covid-19 treatment in more than 20 countries. They include Mexico where the mayor of Mexico City, Claudia Scheinbaum, recently said that the medicine had reduced hospitalisations by as much as 76%. As of last week, 135,000 of the city’s residents had been treated with the medicine. The government of India — the world’s second most populous country and one of the world’s biggest manufacturers of medicines — has also recommended the use of ivermectin as an early outpatient treatment against covid-19, in direct contravention of WHO’s own advice.
Dr Vikas P. Sukhatme, the dean of Emory School of Medicine, recently wrote in a column for the Times of India that deploying drugs such as ivermectin and fluvoxamine in India is likely to “rapidly reduce the number of COVID-19 patients, reduce the number requiring hospitalization, supplemental oxygen and intensive care and improve outcomes in hospitalized patients.”
Four weeks after the government included ivermectin and budesonide among its early treatment guidelines, the country has recorded its lowest case count in 40 days.
In many of India’s regions the case numbers are plunging in almost vertical fashion. In the capital Delhi, as in Mexico City, hospitalisations have plummeted. In the space of 10 days ICU occupancy fell from 99% to 70%. Deaths are also falling. The test positivity ratio slumped from 35% to 5% in just one month.
One of the outliers of this trend is the state of Tamil Nadu, where cases are still rising steeply. This may have something to do with the fact that the state’s newly elected governor, MK Stalin, decided to exclude ivermectin from the region’s treatment protocol in favor of Remdesivir. The result? Soaring cases. Late last week, Stalin reversed course once again and readopted ivermectin.
For the moment deaths in India remain extremely high. And there are concerns that the numbers are being under-reported. Yet they may also begin to fall in the coming days. In all of the countries that have used ivermectin widely, fatalities are the last thing to fall, after case numbers and hospitalizations. Of course, there’s no way of definitively proving that these rapid falloffs are due to the use of ivermectin. Correlation, even as consistent as this, is not causation. Other factors such as strict lockdowns and travel restrictions no doubt also play a part.
But a clear pattern across nations and territories has formed that strongly supports ivermectin’s purported efficacy. And that efficacy has been amply demonstrated in three meta-analyses.
India’s decision to adopt ivermectin, including as a prophylaxis in some states, is already a potential game-changer. As I wrote three weeks ago, if case numbers, hospitalizations and fatalities fall in India as precipitously as they have in other countries that have adopted ivermectin, it could even become a watershed moment. But for that to happen, the news must reach enough eyes and ears. And for that to happen, reporters must, as Capuzzo says, begin to do their job and report both sides of this vital story.
A sea change is underway. Ten years ago, it was heresy to propose that a ketogenic (a.k.a low carb high fat) diet was in any way healthier than the low fat high carb diet supported by public health authorities. It was branded a “gimmick” diet. In some places, doctors who prescribed it to their patients risked having their medical licenses revoked.
The German physicist Max Planck is often misquoted as having said that “science advances one funeral at a time”. Well, the man who gave birth to the low fat high carb dogma, Ancel Keys, died in 2004. His first generation of acolytes have now joined him in oblivion. The men (they were with very few exceptions all men) who created the current dietary guidelines back in the late 70’s and early 80’s are also gone, after having presided over a massive explosion in the number of people suffering from obesity and type 2 diabetes.
The newer generations of nutrition researchers do not appear to be as wedded to the old dogma. This is visible in the increasing number of studies being published on a ketogenic diet. Some of these are even appearing in the most prestigious and conservative nutrition journals.
One such study was recently published in Advances in Nutrition, a journal owned by the American Society for Nutrition. It was a systematic review looking at randomized trials of a ketogenic diet as a treatment for Alzheimer’s disease, which is the most common cause of dementia. We’re going to get to that study in a minute, but first, a little detour.
There is some evidence to support the notion that dementia can in part be caused by a high carbohydrate diet. An observational study was published back in 2012 in The Journal of Alzheimer’s Disease in which 937 elderly people were followed for four years. The median age at the start of the study was 80 years, and at the beginning, all the participants were asked to fill in a diet questionnaire and were also evaluated for cognitive function. Four years later, 200 of the 937 participants had developed some level of cognitive impairment.
When the researchers correlated this with dietary carbohydrate intake, they found that the quartile with the highest intake had an 89% increased relative risk of developing cognitive impairment during the four years of follow-up, as compared to the group with the lowest intake. And that’s after adjusting for known confounders like gender, BMI, co-morbidities, and APOE4 status (APOE4 is a gene variant that is strongly associated with increased risk of Alzheimer disease). The difference was statistically significant (p-value 0.004).
The quartile with the highest fat intake, on the other hand, had a 56% decreased relative risk of cognitive impairment as compared to the quartile with the lowest fat intake (p-value 0.03).
Interestingly, the differences between the quartiles in terms of carbohydrate and fat consumption weren’t actually that big. The highest quartile in terms of carbohydrate consumption was getting more than 58% of calories from carbohydrates, while the lowest quartile was getting less than 47%. Not a huge difference. The same was true for fat intake. The quartile with the highest fat intake was getting more than 35% of calories from fat, while the quartile with the lowest fat intake was getting les than 27%. This would seem to suggest that even relatively modest differences in consumption of carbohydrates and fats can have big effects on cognitive function over time, and that an even bigger reduction in relative carbohydrate intake might have achieved an even bigger reduction in risk of cognitive impairment.
Of course, this was an observational study, and although the results are suggestive, it can’t prove the existence of a cause and effect relationship between carbohydrate/fat intake and dementia. The results could have been caused by residual confounders that the researchers were not able to adjust for. For proof of a cause-effect relationship you need randomized controlled trials. Which is where the recent systematic review published in Advances in Nutrition comes in. As mentioned earlier, it was looking at the randomized trials that exist of a ketogenic diet as a treatment for Alzheimer’s disease and mild cognitive impairment.
Ten trials were identified, with a total of only 456 participants, which really shows how under-researched this area is. And things get worse. Only three of the trials, with a total of only 47 participants, were actually testing a ketogenic diet (i.e. a diet in which carbohydrates are restricted to the point where the body significantly increases production of ketone bodies). The rest were testing supplements containing medium chain triglycerides (MCT’s), which the body preferentially converts to ketones. From my perspective, these are two very different interventions. A ketogenic diet has many different effects on our metabolism, and I am inclined to believe that the beneficial effects come primarily from the reduction in carbohydrates and insulin, not from the increase in ketones.
Taking an MCT containing supplement is obviously not the same thing as following a ketogenic diet. The seven studies of ketogenic supplements were, with only one exception, either funded by companies that sell supplements, or they failed to disclose their funding (which means they were probably funded by companies that sell supplements). Most of these studies were never registered at clinicaltrials.gov, and of the ones that were, this was done after the trials were already underway, which is highly suspect behaviour, because it means the researchers could know wether the trials were going well or not before they let the world know about them. In other words, it’s possible they were simultaneously running other trials that weren’t going so well, and that were therefore never posted on clinicaltrials.gov, which could lead to massive publication bias.
The three small studies of a ketogenic diet compared it with the traditionally recommended low fat high carb diet. One of the three ran for twelve weeks, while the other two ran for six weeks, so these were short term interventions. In terms of outcomes, there were improvements in some of the cognitive functions tested, but not in others. Overall, the results really don’t tell us anything useful, as you would expect from tiny trials run for short periods of time.
The seven studies of MCT supplements appeared to show some benefit in terms of cognitive function in Alzheimer patients, although the fact that these were mostly industry funded studies, that weren’t pre-registered at clinicaltrials.gov, makes the results hard to trust. Strangely, the systematic review only reports whether there was a “benefit” or not, but not what the size of the benefit was, or whether it was statistically or clinically significant. This feels like a rather weird omission in a systematic review. So I decided to look up the two biggest trials, with 152 and 131 participants respectively. According to the systematic review, the first showed an “improvement” in ADAS-Cog (a test of cognitive function used in Alzheimer’s disease) and MMSE (a test for dementia), while the second showed an “improvement” in ADAS-Cog .
When we look at the first of these trials, we find that the difference between the group getting MCT and the placebo group at 104 days (the longest follow-up) was less than one point on the 70 point ADAS-Cog scale. One point on a 70 point scale is not a noticeable difference. Additionally, the difference wasn’t statistically significant. In other words, there was no clinically meaningful or statistically significant difference between the groups on ADAS-Cog. If we move on to MMSE, we find no difference whatsoever between the groups. Yet this study is reported as being “positive” in the systematic review. Odd.
When I moved on and looked at the second of these trials, I immediately realized that it was just a duplicate report of the same study, with a few new analyzes of the same data set. Researchers often do this, to maximize the number of publications they can get out of one data set (since career success in research is largely determined by number of publications). How the authors of the systematic review didn’t realize this is beyond me.
So basically, one negative study was reported as two positive studies in the systematic review. And these were the two “big” studies, supposedly representing 62% of the participants in the systematic review. All the other studies were much smaller.
This weirdness really makes me wonder about the motives of the authors of the systematic review. No conflicts of interest were reported, and they reported receiving no specific funding to carry out the review. But seriously, they went through all this data in detail and didn’t realize that they were looking at the same data set twice! And then, to top it off, Advances in Nutrition, the fourth highest ranked nutrition journal, went ahead and published it, no questions asked!
This really speaks to the poor state of nutrition research more than anything else, and to the low added value provided by the process of peer review. If peer review was the rigorous process that the general public thinks it is, this nonsense would have been noticed and called out, and the article wouldn’t have been published.
What can we conclude?
Athough I am a strong proponent of a ketogenic diet as an effective therapy for metabolic syndrome, obesity and type 2 diabetes, and therefore think it’s likely that it also has beneficial effects in terms of preventing or delaying dementia (which is far more common in people suffering from these diseases), the evidence that exists today cannot prove that that is the case. Nor does the current evidence support the use of MCT supplements as a way to treat or prevent dementia.
Latest analysis shows yet again – yet again – what we already knew from 40 years of published research. And also empirically from simply glancing over the past year’s real-world data. Masks don’t work!
Our main finding is that mask mandates and use are not associated with lower SARS-CoV-2 spread among US states. 80% of US states mandated masks during the COVID-19 pandemic.
Mandates inducedgreater mask compliance but did not predict lower growth rates when community spread was low (minima) or high (maxima). We infer that mandates likely did not affect COVID-19 case growth [15], asgrowth rates were similar on all days between actual or modeled issuance dates and 6 March 2021. Highermask use (rather than mandates per se) has been argued to decrease COVID-19 growth rates [11].
While compliance varies by location and time, IHME estimates are robust (derived from multiple sources [17]) and densely sampled (day-level precision). Higher mask use did not predict lower maximum growth rates, smaller surges, or less Fall-Winter growth among continental states.
Mask-growth rate correlation wasonly evident at minima. This may be an artifact of faster growth at fewer normalized cases, as well asregional differences in case prevalence early in the pandemic. States in the high mask quintile grew atsimilar rates as states in the low mask quintile after maxima (when interstate total case differences weresmaller than before minima).
In addition, mask use did not predict normalized cases at minima, and low mask growth curves trailed those of high mask (particularly Northeast) states before minima. Growthmaxima and Fall-Winter surges did not differ between Northeast and other states. Northeast statesexhibited the highest seroprevalence up to at least July 2020 [24] and constituted 80% of the top quintileof mask use, which may explain their comparatively lower Summer growth.
Overall, mask use appears tobe an intra-state lagging indicator of case growth. There is inferential but not demonstrable evidence that masks reduce SARS-CoV-2 transmission. Animalmodels [25], small case studies [6], and growth curves for mandate-only states [16] suggest that maskefficacy increases with mask use [11]. However, we did not observe lower growth rates over a range ofcompliance at maximum Fall-Winter growth (45-83% between South Dakota and Massachusetts duringmaxima) [17] when growth rates were high.
This complements a Danish RCT from 3 April to 2 June 2020, when growth rates were low, which found no association between mask use and lower COVID-19 rates either for all participants in the masked arm (47% strong compliance) or for strongly compliant participants only [8].
Masks have generally not protected against other respiratory viruses. Higher self-reported mask use protected against SARS-CoV-1 in Beijing residents [26], but RCTs found no differences in PCR confirmed influenza among Hong Kong households assigned to hand hygiene with or without masks (mask use 31% and 49%, respectively) [27].
Medical and cloth masks did not reduce viral respiratory infections among clinicians in Vietnam [9] or China [10], and rhinovirus transmission increased among universally masked Hong Kong students and teachers in 2020 compared with prior years [28].
These findings are consistent with a 2020 CDC meta-analysis [29] and a 2020 Cochrane review update [30].
Our study has implications for respiratory virus mitigation. Public health measures should ethically promote behaviors that prevent communicable diseases. The sudden onset of COVID-19 compelled adoption of mask mandates before efficacy could be evaluated.
Our findings do not support thehypothesis that SARS-CoV-2 transmission rates decrease with greater public mask use.
As masks are required in public in many US states, it is prudent to weigh potential benefits with harms. Masks may promote social cohesion as rallying symbols during a pandemic [31], but risk compensation can also occur [32]. Prolonged mask use (>4 hours per day) promotes facial alkalinization and inadvertently encourages dehydration, which in turn can enhance barrier breakdown and bacterial infection risk [33].
British clinicians have reported masks to increase headaches and sweating and decrease cognitive precision [34]. Survey bias notwithstanding, these sequelae are associated with medical errors [35]. By obscuring nonverbal communication, masks interfere with social learning in children [36]. Likewise, masks can distort verbal speech and remove visual cues to the detriment of individuals with hearing loss; clear face-shields improve visual integration, but there is a corresponding loss of sound quality [37, 38].
Future research is necessary to better understand the risks of long-term daily mask use [30]. Conversely, it is appropriate to emphasize interventions with demonstrated or probable efficacy against COVID-19 such as vaccination [39] and Vitamin D repletion [40]. In summary, mask mandates and use were poor predictors of COVID-19 spread in US states. Case growth was independent of mandates at low and high rates of community spread, and mask use did not predict case growth during the Summer or Fall-Winter waves.
Strengths of our study include using two mask metrics to evaluate association with COVID-19 growth rates; measuring normalized case growth in mandate and non-mandate states at comparable times to quantify the likely effect of mandates; and deconvolving the effect of mask use by examining case growth in states with variable mask use. Our study also has key limitations. We did not assess counties or localities, which may trend independently of state averages.
While dense sampling promotes convergence, IHME masking estimates are subject to survey bias. We only assessed one biological quantity (confirmed and probable COVID-19 infections), but the ongoing pandemic warrants assessment of other factors such as hospitalizations and mortality. Future work is necessary to elucidate better predictors of COVID-19 spread. A recent study found that at typical respiratory fluence rates, medical masks decrease airway deposition of 10-20μm SARS-CoV-2 particles but not 1-5μm SARS-CoV-2 aerosols [41].
Aerosol expulsion increases with COVID-19 disease severity in non-human primates, as well as with age and BMI in humans without COVID-19 [42]. Aerosol treatment by enhanced ventilation and air purification could help reduce the size of COVID-19 outbreaks.
My little boy with autism is back at school, for three days in the week. His support teacher is at last unmasked. On the seventh day of his return, there was an unheralded change. Instead of Joseph being accompanied by his support teacher at pick-up time so that she and I might have a quick chat, he was sent out alone along with his classmates. Inside his bag was a new small notebook, with “Communication Log” written on the cover, in which there were phrases describing aspects of Joseph’s day.
Joseph’s communication is profoundly restricted. He is unable to report any aspect of his physical experience; he cannot tell of anything that has happened to him, no matter how recently. A short exchange, before and after school, with the person responsible for him during the day is essential.
At drop-off time the following morning, Joseph’s support teacher watched helplessly from behind the classroom’s glass door while I held Joseph’s hand at the gate – another of the pathetic scenes that have been a feature of our Covid incarceration. “Mummy’s going to drop you here”, said one of Joseph’s year’s teachers, to me via him. When I objected, she told me, in a rush of what seemed like resentment, that the ‘Communication Log’ was to substitute for the morning and evening chats.
It did not take much representation to the school’s Head to have the chats reinstated; the arguments in their favour were so obviously reasonable. But that the arguments against them were so paltry reveals something concerning, I think.
Even according to ‘The Science’, there could be no conceivable added risk of infection by a respiratory virus in ending a day of up-close support of Joseph by standing in the open air and talking for a few minutes to his mum – to his credit, the Head did not attempt to suggest that there could be.
But if there was nothing actually harmful about these chats, even on the highly-sensitive Covid safety-scale, why were they ruled out so summarily?
Joseph’s support teacher is a woman of great humour; chatting with her is inevitably a lively affair no matter how mundane the topic. But there is something indistinctly offensive now about liveliness of any kind, something excessive, disrespectful.
On our uncertain return to normality there is dawning a new morality, according to which lively human interaction is unseemly simply by virtue of being… well, lively.
This may explain why persecution of the public house continues unabated – insofar as the pub encourages informal and vibrant association, it is the den of a new iniquity: the spontaneous overflow of the human spirit.
At the supermarket checkout the other day, the man in front of me observed through his mask to the woman working the till, how good it is that we have our freedoms back. So long as we use them sensibly, he added.
We have been prodded this year by the devilish theme of safety, which has dramatically altered the contour of our lives. But now the colour of our lives may be changing too, as we are encouraged from all sides not only to stay safe but to be sensible.
On May 15th, the FA Cup final was attended by twenty-two thousand supporters. The fans were back. Football was back. And certainly, the real crowd did foreground how anaemic has been its virtual equivalent. But when Leicester scored the goal that won them the cup, their cheering fans were faced down by a line of officials, caped in plastic over their high-visibility jackets and fanning their outstretched gloved hands, palms downwards, in a calming gesture – Let’s be sensible, folks.
Two days later, May 17th, brought the return of hugging for anyone who had been observing the ban. But it is not a rush-into-the-arms hugging, not a big hugging, not a tight hugging, all of which have about them this new taint of excess. It is sensible hugging: faces turned in opposite directions and got over with as quickly as possible.
There is a new kind of puritanism abroad – casting its pall over our lives, already so out of shape. Those moments when life is brimming over, when we act on impulse, when our sides split with laughter, when we cry with anger or with joy, when we cannot let go our embrace or when we could talk and talk for hours: all have about them a new hue of poor taste. The palate of human life has been dimmed; Let’s be sensible, folks.
In a short blog post from April 16th, the Italian philosopher Giorgio Agamben prepared us for a change of this kind.
Differently from other animals, Agamben wrote, we humans have always the task of deciding what it is that makes us human, and not merely animal.
Homo sapiens is the being that knows itself, the only being on earth that must determine its own essence.
This unique duty – that we decide the kind of being that we are – is what makes us humans so culturally rich and almost infinitely adaptable. But it is also what makes us vulnerable, as no other animal is, to being transformed, profoundly, from the ground up.
Nothing absolute stands in the way of our knowing ourselves differently and knowing ourselves differently changes us utterly.
Is such a change occurring now, as we get back to our new future? Are we in the process of deciding all over again what it is that makes us human?
This would certainly explain the newly muted tones of the life that we are now to live, in which the chatting, the cheering, the hugging that still come naturally to some of us seem suddenly and strangely out of step, not really done, a bit much – Let’s be sensible, folks.
According to Agamben, a society’s decision about what it is that makes us human is reflected in what that society identifies as ‘mere existence’ – bare life. In this space are established the terms on which we claw back from our animal natures whatever it is that is judged to make us human.
We opponents of governments’ Covid policies have traded heavily on this concept of ‘mere existence’, criticising the lockdowns for having reduced our human life to its bare bones.
But in doing so, have we unwittingly lent our voices to a new Covid-era version of ‘mere existence’ and, consequently, to a new Covid-era decision about what it is that makes us human?
Still when I was growing up, references to ‘mere existence’ had mostly to do with work; bare life was the life absorbed by a low-paid unsatisfying job with long hours, or (depressingly) by unwaged care of other people.
If you lived this mere existence, this bare life, you were perilously close to losing that which distinguished you as human – you were said to work like a dog, to have a dog’s life.
If you managed to rise above this mere existence to something better, something more human, you did so also in terms of work. Because a bare life was a life of unwaged drudgery, a full life was a life of satisfying and rewarding employment, and a good life was industrious and purposeful, filled with hobbies and sports at which you were as hardworking as you were at your job.
But since the advent of Covid, when we have bemoaned the reduction of our lives to mere existence, we have referred not to dull work without wages but to quarantine without symptoms. Bare life is no longer the life of unrewarding toil, but of isolation from other people, faces covered and hands sheathed.
The theme of bare life is no longer work but health, where ‘health’ refers, not to a personal equilibrium, but to public safety from invisible attack.
As we have lived this bare life during the past 15 months or so, and tried to reassert our humanness so as to rise above it, it is not the dog’s life against which we have had to define ourselves but the life of the herd animal whose individual hopes and needs are submitted to the advantage of the group: I isolate for everyone, I mask for everyone, I vaccinate for everyone.
Herd immunity has always been a feature of human life. It is a well-established phenomenon in epidemiology. But never before 2020 was it brought before us so unrelentingly that we were simultaneously compelled to reject it as beneath our human status and submitted to the version of it engineered and imposed by governments and their science advisers.
On the new terrain of bare-life-as-isolation-from-and-for-the-herd, we have had to battle all over again to reestablish what makes us human. Human life, we have objected, is more than isolation for the sake of public health. Human life, we have protested, is anathema to distance and to masks.
But we should be careful. Because, if we are beginning to win the battle against the reduction of our lives to mere-existence-as-quarantine, we are likely to be winning it on the terms set up by mere-existence-as-quarantine, that is, on the terms of health-as-safety.
If the society of work is coming to an end, the society of health may be just getting going. In this society, a full life will be the life of optimal protection from identified threats to public safety; and a good life will be the life of due respect for this enterprise, the careful life, the sensible life, in which our human bodies, now branded as traitors, will not be suffered to stretch their limbs too far, nor shout too loud, nor laugh too much, nor hug too tight.
The devil used to make work for idle hands – hence the old morality of working hard. Now the devil makes sickness for loose tongues, and all other body-parts that are brought to bear with gleeful abandon – hence the new morality of being sensible.
What is it that effects a transformation of this magnitude, from a life defined by work and lived industriously to a life defined by health and lived sensibly? How can such changes come about so suddenly and completely? According to Agamben, all it needs is a powerful enough device.
For the society of work, this device was the slave, an idea (rooted in reality, of course) profound enough to capture and recast a whole culture as woven around the theme of work and as haunted by the near-animality of work without reward.
For our society of health, the device is the asymptomatic, an idea (not rooted in reality, it turns out) so powerful that it has captured and recast our world as revolving around the theme of health-as-safety and as haunted by the prospect of disease at the level of the pack.
The device of the asymptomatic sick person has reset the horizons of our lives: the bare life is the life lived apart from the herd for the good of the herd; the full life is the life that is constantly proven to be without sickness itself and protected from the sickness of others: and the good life is the life that abstains from the joyful excess that so irresponsibly forgets that the absence of symptoms does not imply safety.
One of the Internet phenomena of our Covid era has been the film of a flash mob rendition of ‘Danser Encore’ in the Gard du Nord on March 4th.
It has inspired many repeat performances in towns and cities around the world, each one of them a joyful affair.
When I first saw the original video, its effect was profound. To see the sudden eruption, as if from nowhere, of… well, a mob, a glut of people, in the midst of the faceless bedraggle at the station – to see the masks carelessly pulled down or discarded, the random weaving in and out of the crowd, arms linked to the music, to hear singing at the top of fine unmuffled voices. Such a glorious upturning of safety.
But what strikes me now when I watch it is the ludicrousness of the performance, an assemblage of this and that: the tap dancer on her makeshift floor; the circus performer in his Breton top, making upside-down frog-legs; the amateur country dancers; the woman in the mask (around her eyes, not her mouth and nose!) creeping stealthily through the scene… random, heedless, a propos of nothing, not at all sensible.
If we are to unwind the Covid decision about what it is that makes us human – if we are to defuse the device of the asymptomatic spreader and refuse the life of safety to which it consigns us, then we might do worse than begin here, with the players in the Gard du Nord : and dance again and hug again and cheer again and chat again with the lively abandon that spares not a thought for the hidden health-status of ourselves or anyone else.
Dr Sinead Murphy is Associate Researcher in Philosophy at Newcastle University.
Virus Mania in New Zealand: * NZers who would like to order the book locally for $65 (incl. shipping) please contact admin@drsambailey.com Virus Mania Paperback: * Abe (lots of suppliers): https://www.abebooks.com/products/isb…
Are you tired of having to watch everything you say, in case you’re accused of “hate speech”? Do you frequently have to bite back innocently-spoken words, when someone claims to be “offended” by them? Have you become used to avoiding lively debate or expressing frank opinions on social media, for fear of finding police officers on your doorstep?
If so, you’ll be glad to know that at last there is a whole class of people you may attack with impunity; people who may be derided, slandered and ostracised to your heart’s content; people so selfish and stupid that you are fully entitled to incite hatred against them with the full blessing of your government.
These are the Great Unclean: the “anti-vaxxers” who are not just nasty spoilsports, standing between you and the ever-deferred reopening of society, but who continue to waft death and disease through a world which can only be made safe by universal, and repeated, “jabbing”.
The opportunity to indulge in virtuous hate speech has been seized with zest by household names and obscure Twitterati alike.
“Love the idea of covid vaccine passports for everywhere,” enthuses Piers Morgan, “restaurants, clubs, football, gyms, shops etc. It’s time covid-denying, anti-vaxxer loonies had their bullshit bluff called and bar themselves from going anywhere that responsible citizens go.”
I hear what you say about someone exercising their freedom not to have a vaccination and they’re perfectly healthy. I don’t want them sitting next to me in the theatre. I don’t want them standing next to me at the theatre bar. I don’t want them next to me or anywhere near me or even in the same carriage on the train. So they can exercise their freedom by staying at home.”
As for the chorus of the immunologically saved on social media, here’s a sample meme:
If you’re antivax and you see me making fun of antivax people, I just want to say I’m talking about you personally and I hope you’re offended because you’re fucking stupid.”
Just try substituting one of a whole range of tenderly protected diversities for “antivax people” or “anti-vaxxers”, and watch the frisson of outrage creeping down any bien-pensant spine. But as the State extends its tolerance, even its encouragement, to our abusers, we covid sceptics, it seems, are fair game.
For there is no quarter from the government for those who are standing aloof from the stampede to get “shots into arms”, as believers in the WHO’s revised definition of herd immunity so crudely like to put it.
This is, after all, a government which, spurred on by behavioural psychologists and with malice aforethought, has industriously stirred up and exploited social disapproval as a potent means of shaming dissent and achieving maximum compliance.
Be kind, they urge you, and deprive yourself and your children of oxygen for your neighbour’s sake. Be responsible, and roll up your sleeve to receive the magic injection that will not only make you immortal but demonstrate your selfless concern for others. Don’t be stupid! Remember, having no symptoms doesn’t mean you’re not a silent super-spreader.
But do sceptics really deserve the contempt being dished out to them so freely?
Are they really so stupid?
Would any self-respecting “anti-vaxxer”, for instance, have been silly enough to come out with the nonsense spouted by the UK’s secretary of state for health, when he told us that:
If you think about it, the vaccine is a tiny bit of the virus in order to get your body to be able to respond.”
Really, Mr Hancock? Are you sure that’s what’s actually on offer here?
Perhaps Mike Yeadon, former head of respiratory research at Pfizer, can set you straight. As he pointed out to James Delingpole recently, “a tiny bit of the virus” is not what goes into these novel treatments – perhaps because, when it comes down to brass tacks, “no-one’s got any”.
What is actually being pumped into millions of arms throughout the world with such careless abandon is not, he says, “just a vaccine”. Although these gene-based medications do “ultimately raise an immune response … the way they do it is completely different from any vaccine we’ve used before … they induce the body, the cells of your body, to actually manufacture a piece of this pathogen, this infective agent. And you respond to that.”
“Anti-vaxxers” could have told you that, Mr Hancock, because they’ve done their own research, and they understand the difference between the traditional idea of a vaccine and what is currently being held up as the golden ticket to freedom. So please stop feeding us blatant untruths about what is actually being injected into all those trusting arms and making its insidious way around millions of bloodstream.
Let’s have the facts that would enable everyone to make a truly informed decision. It really doesn’t help when you fuel sectarian hatred by standing up in parliament and declaring that:
those who promulgate lies about the dangers of vaccines that are safe and have been approved … are threatening lives …”
The obvious response to that is, “those who promulgate lies about the safety of novel and incompletely tested gene therapies doled out on emergency approval only are threatening lives.”
The life of Peter Meadows, for instance: a superlatively healthy seventy-six-year-old, who, trusting government and NHS assurances that the “vaccines” were “safe and effective”, suffered an unprecedented heart attack within hours of receiving the Pfizer jab, and died a few days later: just one of over a thousand post-vaccine fatalities officially logged in the UK’s Yellow Card system to date – or perhaps, as the evidence is increasingly suggesting, of thousands of vaccine-related deaths which, unlike those ascribed to Covid, are not in line with natural mortality profiles.
It seems that those castigated for being “anti-vaxxers” are, in fact, far from stupid. On the contrary, they are the ones sensible enough to take the time and trouble to research and weigh up risks versus benefits before exposing their bodies to any of the novel gene therapies currently being hawked around as “vaccines”.
It is those who don’t search out the facts for themselves who are not using their intelligence, and who are thereby laying themselves open to the smooth sales talk of drug pushers in high places. Peter Meadows and his wife were apparently not handed even the minimal information supplied by the NHS regarding possible side effects they might suffer until after they had received their shots.
They had no idea that the “vaccines” so confidently touted by Matt Hancock were not fully tested for immediate, let alone medium- or long-term, safety, and were issued under the “black triangle” system – ie, were still “subject to intensive safety monitoring”, with the proviso that a record should be kept of all adverse reactions experienced by those acting effectively as human guinea pigs on behalf of the pharmaceutical companies.
What is more, a “high volume” of such adverse reactions were anticipated by the apparently unconcerned UK government before the roll-out began.
Although the Royal Pharmaceutical Society is quick to state that the black triangle label “does not indicate that the product is unsafe for use in patients”, the common-sense response to such a claim, after careful examination of the Yellow Card data, must surely be, “Oh yeah? And now pull the other one!”
In fact, a Pubmed paper advising the US as to whether or not the black triangle system does indeed promote “more judicious prescribing” of new medications, concludes that, “Accelerated drug approvals could cause more uncertainty about drug effectiveness and safety, but specific labeling of newly approved medicines is unlikely to promote more judicious prescribing.”
How much more accelerated could approval be, than the emergency approval accorded to the new coronavirus “vaccines”? And how much less judicious their prescribing, encompassing, as it does, the wholesale jabbing of populations throughout the world, including young people and children, who are at little to no risk of succumbing to the disease, let alone dying of it? It is depressing to learn that Peter Meadows’ daughters had understood enough about the uncertain nature of the hastily concocted “vaccines” to urge their parents not to have the jabs.
Unfortunately, like so many others, the couple were swayed by a longing to return to their old normal, and by peer pressure whipped up by the likes of Matt Hancock and SAGE, rather than by the reasonable concerns raised by their daughters after careful scrutiny of the facts.
Many of them “express mistrust for academic and journalistic accounts of the pandemic, proposing to rectify alleged bias by ‘following the data’ and creating their own data visualisations.” What they value is “unmediated access to information” and they “privilege personal research and direct reading over ‘expert’ interpretations.” And “Most fundamentally,” say the MIT team, “the groups we studied believe that science is a process, and not an institution.”
Exactly.
In which case, their dismissal of the WHO’s presumption, in claiming to be custodians of “The Science”, is hardly surprising. Nonsense, say the sceptics. Science can never be above questioning. It is not a bundle of rubber-stamped, government-approved dogmas, handy for facilitating some political or commercial agenda.
Like all forms of human knowledge, science remains eternally incomplete, the evolving construction of many minds researching truth in a continuing process of discovery: forming hypotheses, and attempting by all means possible to disprove those hypotheses; seeking to explain or resolve anomalies, but never holding any theory sacrosanct which further investigation might yet prove false; adapting to the gradual unfolding of new perspectives, as fresh evidence shakes the foundations of old paradigms.
It is the alleged “covidiots” and “anti-vaxxers” who, while they may not be scientists themselves, understand the principles on which the scientific method is based. As the MIT study admits, to complain that these irritating people “need more scientific literacy is to characterize their approach as uninformed and inexplicably extreme. This study shows the opposite: they are deeply invested in forms of critique and knowledge production they recognise as scientific expertise.”
All the same, the authors of the study seem to find the concessions they are compelled to make disturbing. “(H)ow do these groups diverge from scientific orthodoxy,” they wonder, “if they are using the same data?” Since all right-minded facts should show decent respect for the statutory consensus, surely anyone inducing them to defect in support of alternative, unsanctioned conclusions must be employing underhand methods?
“We have identified a few sleights of hand that contribute to the broader epistemological crisis we identify between these groups and the majority of scientific researchers,” the defenders of the true faith plead: and they shake their heads at the way “these groups skillfully manipulate data to undermine mainstream science,” quoting as examples the sceptics’ “outsize emphasis on deaths versus cases” and their suspicion of the officially promoted confusion of deaths “with” and “of” covid: both very good reasons, less partial analysts might say, for questioning the figures being spewed out ceaselessly by the government-funded mainstream media, and taken by a terrorised public to be gospel truth.
Yet it’s not just annoying amateurs, with their absurd claims that actual facts should trump any institutionally-coerced consensus, who question the official “narrative” – and, indeed the very existence of a pandemic, as traditionally understood before the WHO decided to “re-imagine” the term, on 4th May 2009, in anticipation of the projected swine-flu apocalypse (in the event, a damp squib, but a useful practice-run for the present resounding success).
After accumulating hard evidence in interviews with over a hundred eminent scientists and other experts, the Corona Investigation Committee, a team headed by Dr Reiner Fuellmich, are likewise challenging the means – essentially, a fraudulent PCR test capable of manufacturing cases on demand and fuelling the myth of the “asymptomatic superspreader” – by which the global coup and its predestined outcome, the push to “get jabs into arms”, have been so artfully engineered.
Dr Fuellmich – a lawyer qualified to practise in both the States and Europe – has already taken on such giants as Deutschebank and Volkswagen. We can only hope that the evidence which he and the rest of the Committee have gathered so painstakingly over the past year and shared with lawyers all over the world will continue to result in court cases where facts will triumph over consensus, vindicating the unvaccinated of “stupidity” before they are forced by the uninformed to wear yellow stars and find themselves rounded up in camps for the unclean.
And that those behind the coup, along with all who enabled and enforced their unlawful actions by “just following orders”, are brought to justice before an international tribunal, to be charged with what the Corona Committee describes as “the greatest crime against humanity ever committed.”
Back in April, I wrote about a study published in Proceedings of the National Academy of Sciences, which found that Dutch students made “made little or no progress while learning from home”. Now researchers have reported a similar finding in Brazil.
As in the Dutch study, the researchers used rigorous methods to gauge the impact of remote learning on student outcomes. In other words, they didn’t just compare outcomes in 2020 to those the year before.
In São Paulo State (where the study was based) state schools switched to remote learning only at the end of the first quarter, and they continued to teach remotely thereafter. This allowed the researchers to compare the change in outcomes between the first and last quarters of 2020 to the change in outcomes between the same two quarters of 2019.
They looked at two different outcomes: high dropout risk (i.e., whether the student had any math and Portuguese grades on his school record in the relevant quarter), and standardised test scores.
When comparing the change in 2020 to the change in 2019, the researchers found large increases in school dropout and learning losses.
Furthermore, they exploited a natural experiment to gauge the impact of switching back to in-person learning. In the fourth quarter of 2020, some municipalities allowed high-schools but not middle-schools to switch back. This allowed the researchers to compare middle- and high-schools in those municipalities with respect to the change in 2020 versus the change in 2019.
Consistent with the previous result, they found that switching back to in-person learning was associated with higher standardised test scores.
In the authors’ own words, their results show that “the societal costs of keeping schools closed in the pandemic are very large”. As such, they argue that “the public debate should move from whether schools should be open or not to how to reopen them safely”.
Dr. Peter McCullough has been the world’s most prominent and vocal advocate for early outpatient treatment of SARS-CoV-2 (COVID-19) Infection in order to prevent hospitalization and death. On May 19, 2021, he was interviewed about his efforts as a treating physician and researcher. From his unique vantage point, he has observed and documented a PROFOUNDLY DISTURBING POLICY RESPONSE to the pandemic — a policy response that may prove to be the greatest malpractice and malfeasance in the history of medicine and public health.
Dr. McCullough is an internist, cardiologist, epidemiologist, and Professor of Medicine at Texas A & M College of Medicine, Dallas, TX USA. Since the outset of the pandemic, Dr. McCullough has been a leader in the medical response to the COVID-19 disaster and has published “Patho-physiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection” the first synthesis of sequenced multi-drug treatment of ambulatory patients infected with SARS-CoV-2 in the American Journal of Medicine and subsequently updated in Reviews in Cardiovascular Medicine. He has 40 peer-reviewed publications on the infection and has commented extensively on the medical response to the COVID-19 crisis in The Hill and on FOX NEWS Channel. On November 19, 2020, Dr. McCullough testified in the US Senate Committee on Homeland Security and Governmental Affairs and throughout 2021 in the Texas Senate Committee on Health and Human Services, Colorado General Assembly, and New Hampshire Senate concerning many aspects of the pandemic response.
Major benefits of ivermectin (IVM) treatment for COVID-19 have been known since the results of 20 such randomized controlled trials (RCTs) were reported, as compiled in January 2021. Of the eight of these RCTs that tracked mortality or morbidity in patients with serious cases, seven showed statistically significant clinical improvements. The pooled mortality reduction in these eight RCTs was 78% in the treatment vs. controls groups, and the RCT that used the highest dose of IVM reported a 92% reduction in mortality (p < 0.001). Three RCTs for IVM prevention of COVID-19 and two animal studies of IVM at low human-equivalent doses likewise reported pronounced efficacy. Here we note the recent publication of RCTs for IVM treatment or prevention of COVID-19 in mainstream scientific journals that confirm these previously reported findings.
Background
The consistently observed, major benefits of ivermectin (IVM) for COVID-19 treatment have been known since a January 2021 meta-study compiled results of 20 such randomized clinical trials (RCTs).1 Of the eight of these RCTs that tracked mortality or morbidity in patients with moderate or severe symptoms (4 double-blind,2-5 1 single-blind,6 and 3 non-blinded7-9), seven showed statistically significant clinical improvements (all but Podder et al.8). The pooled mortality reduction in these eight RCTs for the IVM treatment group vs. controls was 78% (mortality of 2.1% for IVM, 9.5% for controls). The RCT that used the highest dose of IVM, 1,600 μg/kg total, had 2 vs. 24 deaths in the treatment vs. control group (n=200 each),7 a 92% reduction in mortality (p < 0.001).
Complementing these IVM treatment studies, three RCTs evaluated IVM for prevention in subjects exposed to COVID-19 patients. These studies reported relative COVID-19 incidences of 20%, 16% and 13% compared with incidences in controls, with even lower relative incidences for serious such cases. In addition, two animal studies of IVM treatment at low human-equivalent doses for SARS-CoV-2 in hamsters10 and for a closely related betacoronavirus in mice11 likewise found major, highly statistically significant treatment benefits.
Yet some skeptical reviewers had dismissed this overwhelming RCT evidence for clinical efficacy of IVM against COVID-19, claiming insufficient quality of the studies,12,13 as had been indicated by the lack of publication of any in mainstream scientific journals. The recent publication of five such RCTs for IVM in top-tier journals, including Lancet eClinicalMedicine14 and BMC infectious diseases,15 all reporting major, statistically significant clinical benefits against COVID-19, dismantles these skeptical critiques.
Five recently published studies in mainstream scientific journals
Among these five recently published RCTs was a prevention study of April 2021 by Seet et al.16 IVM was administered to 617 subjects, with 2,420 other subjects assigned to either a control group or to one of three other preventative regimens. The subjects were then tracked for onset of COVID-19 symptoms and positive nasopharyngeal PCR tests over a 42-day period. IVM at a dose of 12 mg was given just once on day one, while the three other preventative regimens were each administered daily during this 42-day period. Yet IVM at this single low dose yielded the best clinical results, reducing incidence of symptomatic COVID-19 by 50% (p=0.003) and of ARDS symptoms by 49% (p=0.012) with respect to controls. IVM at that single low dose, however, yielded only a non-significant 8% reduction in relative incidence of positive PCR tests.
Of the four recently published RCTs that studied IVM treatment of COVID-19, Chaccour et al., as previously released in preprint, monitored outcomes for 40 generally young patients with mild COVID-19 symptoms.14 A single dose of IVM at 400 μg/kg significantly reduced the duration of hyposmia/anosmia (p<0.001), but gave only a modest reduction in viral load. Shahbaznejad et al. reported that IVM in a single dose of 200 μg/kg reduced duration of COVID-19 symptoms and hospitalization (p=0.02 for each).17 IVM also reduced duration of coughing (p=0.02) and of shortness of breath (p<0.05). No conclusions could be drawn regarding mortality, since only one patient died, within 24 hours of hospitalization in critical condition, a 78-year old woman in the treatment group with a history of diabetes and heart failure.
Mahmud et al. administered a single dose of IVM at 12 mg plus doxycycline at 100 mg twice daily for five days.18 The IVM treatment group had statistically significant clinical benefits v. controls by four different measures, p=0.001 to 0.003, and had a reduced percentage of positive PCR tests at 14 days with p=0.002. Okumus et al. administered IVM at 200 μg/kg for five consecutive days, in addition to the standard of care used for both the treatment and control groups, which included azithromycin.15 At the end of the five-day study follow-up period, spO2 was increased; CRP, ferritin and D-dimer blood levels were reduced; and percentage of PCR-negative tests were increased vs. controls, all to statistical significance (p=0.032, 0.02, 0.005, 0.03, and 0.01, respectively).
More pronounced reduction by single-agent IVM of COVID-19 morbidity v. infectivity
The findings of two of these five recently published RCTs, Chaccour et al.14 and Seet et al.,16 both fit a pattern established in a prior RCT3 and two animal studies10,11 of more pronounced alleviation by IVM as a single agent of COVID-19-related symptoms and morbidities than reductions in viral load. Indeed, one RCT of IVM at an unusually high dose, 3,000 μg/kg total over 5 consecutive days, yielded a statistically significant reduction in viral load in COVID-19 patients vs. controls only for the subgroup of treated patients (45%) in which the highest levels of plasma IVM levels were obtained.19
This disparity between reduction in morbidity vs. infectivity by IVM for COVID-19 may be explainable by the indicated clinically operative biological mechanism of IVM as reported in seven molecular modeling studies.20-26 Those studies found that IVM bound strongly to regions of SARS-CoV-2 viral spike protein, one subdomain of which (RBD) controls viral binding and replication via host cell ACE2 receptors, with another subdomain (NTD) governing viral attachments to sialic acid (SA) binding sites on blood, endothelial and other host cells.27 The latter such attachments of SARS-CoV-2 to SA binding sites on red blood cells (RBCs) are responsible for the clumping that is observed in vitro when virus is mixed with RBCs in this hemagglutinating virus. Whereas the common cold human betacoronavirus strains contain an enzyme, hemagglutinin esterase (HE), that releases viral-RBC clumps, the three virulent betacoronavirus strains—SARS-CoV-2, SARS-CoV, and MERS—lack HE.27 IVM, if it is found to bind to NTD sites on SARS-CoV-2 spike protein, might thus limit viral virulence by blocking such hemagglutinating bindings.
The biological mechanism of IVM that is operative clinically against COVID-19 remains to be confirmed, as do indications of its greater reduction of morbidity than of infectivity per the studies noted. The recent publication of the five RCTs noted in top tier scientific journals, however, positively confirms the major, statistically significant clinical benefits of IVM, as previously reported in several prior such RCTs, for COVID-19 treatment and prevention.
References
1. Hill A, Abdulamir A, Ahmed S, et al. Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection. Research Square. 2021;doi:10.21203/rs.3.rs-148845/v1.
2. Babalola O, Bode C, Ajayi A, et al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double blind dose response study in Lagos. medRxiv. 2021;doi:10.1101/2021.01.05.21249131.
3. Kirti R, Roy R, Pattadar C, et al. Ivermectin as a potential treatment for mild to moderate COVID-19 – A double blind randomized placebo-controlled trial. medRxiv. 2021;doi: 10.1101/2021.01.05.21249310.
5. Niaee MS, Gheibi H, Namdar P, et al. Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients; A randomized multi-center clinical trial. Research Square. 2020;doi:10.21203/rs.3.rs-109670/v1.
6. Hashim HA, Maulood MF, Rasheed AM, et al. Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq. medRxiv. 2020;doi:10.1101/2020.10.26.20219345.
7. Elgazzar A, Hany B, Abo Youssef S, et al. Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic. Research Square. 2020;doi:10.21203/rs.3.rs-100956/v1.
8. Podder CS, Chowdhury N, Sina MI, et al. Outcome of ivermectin treated mild to moderate COVID-19 cases; a single-centre, open-label, randomised controlled study. IMC J Med Sci. 2020;14(2):002.
10. Melo GD, Lazarini F, Larrous F, et al. Anti-COVID-19 efficacy of ivermectin in the golden hamster. bioRxiv. 2020;doi:10.1101/2020.11.21.392639.
11. Arévalo AP, Pagotto R, Pórfido JL, et al. Ivermectin reduces in vivo coronavirus infection in a mouse experimental model. Scientific Reports. 2021;11(1):7132.
14. Chaccour C, Casellas A, Blanco-Di Matteo A, et al. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine. 2021;10.1016/j.eclinm.2020.100720.
15. Okumuş N, Demirtürk N, Çetinkaya RA, et al. Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients. BMC Infectious Diseases. 2021;21(1):411.
16. Seet RCS, Quek AML, Ooi DSQ, et al. Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial. International Journal of Infectious Diseases. 2021;106:314-322.
17. Shahbaznejad L, Davoudi A, Eslami G, et al. Effect of ivermectin on COVID-19: A multicenter double-blind randomized controlled clinical trial. Clinical Therapeutics. 2021;https://doi.org/10.1016/j.clinthera.2021.04.007.
18. Mahmud R, Rahman MM, Alam I, et al. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial. Journal of International Medical Research. 2021;49(5):03000605211013550.
19. Krolewiecki A, Lifschitz A, Moragas M, et al. Antiviral effect of high-dose ivermectin in adults with COVID-19: a pilot randomised, controlled, open label, multicentre trial. SSRN. http://ssrn.com/abstract=3714649. Published 2020. Accessed November 23, 2020.
20. Dayer M. Coronavirus (2019-nCoV) Deactivation via Spike Glycoprotein Shielding by Old Drugs, Bioinformatic Study. Preprints.org. 2020;doi:10.20944/preprints202005.0020.v1.
21. Hussien MA, Abdelaziz AEM. Molecular docking suggests repurposing of brincidofovir as a potential drug targeting SARS-CoV-2 ACE2 receptor and main protease. Network Modeling Analysis in Health Informatics and Bioinformatics. 2020;9(1):56.
22. Suravajhala R, Parashar A, Malik B, et al. Comparative Docking Studies on Curcumin with COVID-19 Proteins. Preprints.org. 2020;doi:10.20944/preprints202005.0439.v2.
23. Nallusamy S, Mannu J, Ravikumar C, et al. Shortlisting Phytochemicals Exhibiting Inhibitory Activity against Major Proteins of SARS-CoV-2 through Virtual Screening. Research Square. 2020;doi:10.21203/rs.3.rs-31834/v1.
24. Kalhor H, Sadeghi S, Abolhasani H, et al. Repurposing of the approved small molecule drugs in order to inhibit SARS-CoV-2 S protein and human ACE2 interaction through virtual screening approaches. Journal of Biomolecular Structure and Dynamics. 2020;10.1080/07391102.2020.1824816:1-16.
25. Agrawal L, Poullikkas T, Eisenhower S, et al. Viroinformatics-Based Analysis of SARS-CoV-2 Core Proteins for Potential Therapeutic Targets. Antibodies (Basel). 2021;10(1).
26. Toor HG, Banerjee DI, Lipsa Rath S, et al. Computational drug re-purposing targeting the spike glycoprotein of SARS-CoV-2 as an effective strategy to neutralize COVID-19. Eur J Pharmacol. 2021;890:173720.
27. Scheim DE. From cold to killer: How SARS-CoV-2 evolved without hemagglutinin esterase to agglutinate, then clot blood cells in pulmonary and systemic microvasculature. http://ssrn.com/abstract=3706347. Published 2020. Accessed March 30, 2021.
A new report, published just yesterday, has provided yet more evidence that the CDC is manipulating data to conceal the number of “breakthrough infections”.
A “breakthrough infection” (or “breakthrough case”) is defined as a person who tests positive for Sars-Cov-2 infection, despite already being fully vaccinated. And this new report finds that the CDC’s official record of breakthrough cases is:
likely a substantial undercount.
Going on to explain:
The national surveillance system relies on passive and voluntary reporting, and data might not be complete or representative. Many persons with vaccine breakthrough infections, especially those who are asymptomatic or who experience mild illness, might not seek testing.
Which is partially accurate, but also a pretty major lie by omission.
It is probably true that vaccinated people with no symptoms are unlikely to seek testing, but it is also true that, on March 17th, the CDC updated their advice on testing policy to specifically exclude such people from testing protocols:
Screencap of CDC’s testing guidelines
So, while it’s certainly true that “breakthrough cases” are likely a substantial undercount, it is dishonest to pretend that this is just an accident of the system. Rather, the system is specifically designed to hide such cases.
Of course, this report only goes up to the end of April, the “undercount” will only have gotten worse since then, because the CDC changed their rules AGAIN to make it even harder to keep an accurate count of breakthrough cases.
As we wrote last week, as of May 1st the CDC will no longer be counting mild or asymptomatic cases as “breakthrough infections”, choosing to focus only on hospitalisations and deaths.
According to the CDC’s own report, though, over a quarter (27%) of breakthrough infections were asymptomatic, and a further 61% were only mildly ill. Conversely, only 10% of them were ever hospitalised, and only 2% died:
Based on preliminary data, 2,725 (27%) vaccine breakthrough infections were asymptomatic, 995 (10%) patients were known to be hospitalized, and 160 (2%) patients died.
So, the CDC has taken their “substantial undercount”, and then slashed it by 90%. The official figures, moving forward, will be so inaccurate as to be completely useless.
The CDC claims these changes “will help maximize the quality of the data collected on cases of greatest clinical and public health importance.” But that is an obvious and absurd lie.
Statistical studies have shown up to 86% of Covid “cases” never experience symptoms. To exclude such cases from your vaccine effectiveness studies is to poison your data in order to prop up a pre-determined conclusion. It is, at the very best, extremely poor science.
Of course, the truth is far more cynical even than that.
From the beginning of the so-called “pandemic”, waves of asymptomatic “cases” were deliberately created by running unreliable PCR tests on 100,000s of perfectly healthy people every day.
The entirely predictable false positives were called “cases”, and these manufactured “cases” of Covid19 were used to build up the illusion of a global plague.
This was a prolonged campaign of deception in order to bring about sweeping changes in the construction of our society.
To this point “asymptomatic cases” have been the backbone of the Covid narrative. But now the CDC has attempted to remove them from the reckoning by instructing medical labs and hospitals around the country to stop looking for them, but only in those who have had the “vaccine”.
This is a new prolonged campaign of deception, spinning the narrative that these untested, experimental “vaccines” truly are “effective” against a “pandemic” that was built on statistical smoke and mirrors.
In short: before the vaccine they needed “asymptomatic infections” to create a “problem”, after the vaccine they are actively hiding “asymptomatic infections”, because their existence undermines their “solution”.
“Breakthrough infections”, existing in anything approaching large numbers, effectively means one of three things is true: either the tests are unreliable, the “vaccines” are ineffective…or both.
To anyone interested in the truth, keeping an accurate count of these “breakthrough infections” is therefore vitally important.
The corollary of that, of course, is that anyone attempting to conceal, minimise or ignore them is NOT interested in the truth. Such behaviour is, in fact, a tacit admission of deception.
A professor with the Johns Hopkins School of Medicine has said that there is a general dismissal of the fact that more than half of all Americans have developed natural immunity to the coronavirus and that it constitutes “one of the biggest failures of our current medical leadership.”
Dr. Marty Makary made the comments during a recent interview, noting that “natural immunity works” and it is wrong to vilify those who don’t want the vaccine because they have already recovered from the virus.
Makary criticised “the most slow, reactionary, political CDC in American history” for not clearly communicating the scientific facts about natural immunity compared to the kind of immunity developed through vaccines.
“There is more data on natural immunity than there is on vaccinated immunity, because natural immunity has been around longer,” Makary emphasised.
“We are not seeing reinfections, and when they do happen, they’re rare. Their symptoms are mild or are asymptomatic,” the professor added.
“Please, ignore the CDC guidance,” he urged, adding “Live a normal life, unless you are unvaccinated and did not have the infection, in which case you need to be careful.”
“We’ve got to start respecting people who choose not to get the vaccine instead of demonizing them,” Makary further asserted.
The likes of the World Health Organisation have even shifted the definition of ‘herd immunity’, eliminating the pre-COVID scientific consensus that it could be achieved by allowing a virus to spread through a population, and insisting that herd immunity comes solely from vaccines.
This site is provided as a research and reference tool. Although we make every reasonable effort to ensure that the information and data provided at this site are useful, accurate, and current, we cannot guarantee that the information and data provided here will be error-free. By using this site, you assume all responsibility for and risk arising from your use of and reliance upon the contents of this site.
This site and the information available through it do not, and are not intended to constitute legal advice. Should you require legal advice, you should consult your own attorney.
Nothing within this site or linked to by this site constitutes investment advice or medical advice.
Materials accessible from or added to this site by third parties, such as comments posted, are strictly the responsibility of the third party who added such materials or made them accessible and we neither endorse nor undertake to control, monitor, edit or assume responsibility for any such third-party material.
The posting of stories, commentaries, reports, documents and links (embedded or otherwise) on this site does not in any way, shape or form, implied or otherwise, necessarily express or suggest endorsement or support of any of such posted material or parts therein.
The word “alleged” is deemed to occur before the word “fraud.” Since the rule of law still applies. To peasants, at least.
Fair Use
This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more info go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material from this site for purposes of your own that go beyond ‘fair use’, you must obtain permission from the copyright owner.
DMCA Contact
This is information for anyone that wishes to challenge our “fair use” of copyrighted material.
If you are a legal copyright holder or a designated agent for such and you believe that content residing on or accessible through our website infringes a copyright and falls outside the boundaries of “Fair Use”, please send a notice of infringement by contacting atheonews@gmail.com.
We will respond and take necessary action immediately.
If notice is given of an alleged copyright violation we will act expeditiously to remove or disable access to the material(s) in question.
All 3rd party material posted on this website is copyright the respective owners / authors. Aletho News makes no claim of copyright on such material.